Privi Speciality Chemicals Ltd (PRIVISCL)
🎯 Key Takeaways
- Privi Speciality Chemicals Ltd is in a growth phase driven by capacity expansion, strategic consolidation, and long-term margin targets, supported by strong profitability and disciplined capital allocation. Management is executing a multi-year CAPEX plan to scale operations while maintaining financial stability and shareholder returns.
- Revenue declined 7.7% QoQ to ₹666 in Q1FY27.
- ⚠️ 1) High export dependency (66% of business) exposes the company to global demand and currency volatility. 2) Raw material cost stability is assumed bu
📖 The Story
Privi Speciality Chemicals Ltd is in a growth phase driven by capacity expansion, strategic consolidation, and long-term margin targets, supported by strong profitability and disciplined capital allocation. Management is executing a multi-year CAPEX plan to scale operations while maintaining financial stability and shareholder returns.
📰 What's Happening
The company approved unaudited Q1 FY27 results showing 19.22% YoY revenue growth to Rs 666 crore and 25% operating margins, alongside a final dividend of Rs 10 per share. The Board advanced the Scheme of Amalgamation with Privi Fine Sciences to the NCLT for year-end approval and confirmed Phase-1 capacity expansion to 54,000 MT by September 2026. Management also updated long-term targets of Rs 5,000 crore revenue and Rs 1,000 crore EBITDA within 3-4 years, backed by Rs 850-900 crore Phase-2 CAPEX through 2028.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 679 | 605 | 722 | 666 |
| Operating Profit | 146 | 116 | 144 | 115 |
| OPM % | 21.6% | 19.2% | 19.9% | 17.3% |
| Net Profit | 90 | 75 | 94 | 83 |
| EPS | ₹24.04 | ₹19.97 | ₹23.99 | ₹21.56 |
Revenue growth has moderated slightly in recent quarters, with Q1 FY27 revenue at Rs 666 crore (down from Rs 722 crore in Q4 FY26), but operating margins remain stable at 25%. Net profit and EPS declined marginally in Q1 FY27 to Rs 83 crore and Rs 21.56, yet the company maintained healthy profitability with OPM holding at 17.3%. The slight revenue dip appears consistent with seasonal or operational variability, but margin discipline and stable raw material costs (52-54% of sales) suggest effective cost management amid expansion.
🔮 Management Outlook & What's Next
Management expressed confidence in achieving Rs 5,000 crore revenue and Rs 1,000 crore EBITDA within 3-4 years, underpinned by ongoing capacity expansion, Phase-2 CAPEX of Rs 850-900 crore through 2028, and the biomass pilot plant scaling to commercial operations within 12-15 months. They emphasized that the merger with Privi Fine Sciences is on track for NCLT approval by year-end, and long-term growth is tied to sustainable product innovation and export markets.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 39 | 39 | 39 | 39 |
| Reserves | 953 | 1,064 | 1,201 | 1,373 |
| Borrowings | 1,053 | 1,143 | 1,072 | 1,010 |
| Total Liabilities | 2,457 | 2,791 | 2,957 | 3,170 |
| Fixed Assets | 960 | 1,145 | 1,090 | 1,185 |
| Investments | 9 | 8 | 20 | 55 |
| Total Assets | 2,457 | 2,791 | 2,957 | 3,170 |
The balance sheet shows a stable capital structure with equity held steady at Rs 39 crore and reserves growing from Rs 1,064 crore (Mar 2025) to Rs 1,373 crore (Mar 2026), indicating retained earnings. Borrowings have slightly decreased to Rs 1,010 crore from Rs 1,143 crore, resulting in a net debt/EBITDA ratio of 1.29x, which reflects improved leverage. This suggests management is managing debt prudently while funding growth through a mix of internal accruals and controlled borrowing.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +550 |
| Investing | -358 |
| Financing | -198 |
| Net Cash Flow | -6 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 69.9% | 60.6% | 60.6% | 60.6% |
| FII | 1.3% | 1.6% | 1.4% | 1.9% |
| DII | 4.5% | 10.3% | 10.7% | 10.1% |
| Public | 15.4% | 15.4% | 18.2% | 17.7% |
| # Shareholders | 28,203 | 32,016 | 34,415 | 44,875 |
Promoter holding remains stable at 60.6% over the last four quarters, indicating confidence in long-term prospects. Institutional interest has risen, with FII shareholding increasing from 1.33% (Q2FY26) to 1.94% (Q1FY27), while DII holdings have remained relatively steady around 10%. The growing number of shareholders (44,875 in Q1FY27) suggests increasing retail and institutional participation, though promoter dilution is minimal.
⚖️ Peer Comparison — Chemicals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| PIDILITIND | 1.67 L Cr | 63.2 | 33.4% | 24.7% | 0.01 |
| SRF | 76,535 | 35.4 | 15.6% | 15.4% | 0.36 |
| LINDEINDIA | 54,418 | 99.6 | 17.5% | 12.8% | 0.00 |
| FLUOROCHEM | 52,063 | 85.1 | 9.6% | 7.7% | 0.34 |
| NAVINFLUOR | 44,292 | 56.0 | 22.2% | 19.9% | 0.31 |
| GODREJIND | 38,842 | 33.0 | 9.2% | 19.8% | 4.57 |
| HSCL | 34,339 | 42.7 | 20.7% | 17.1% | 0.16 |
| DEEPAKNTR | 24,328 | 31.1 | 15.3% | 13.4% | 0.26 |
| AETHER | 22,349 | 94.8 | 13.8% | 10.6% | 0.08 |
| AARTIIND | 19,030 | 35.8 | 9.2% | 9.5% | 0.68 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) High export dependency (66% of business) exposes the company to global demand and currency volatility. 2) Raw material cost stability is assumed but not guaranteed, with management noting 52-54% of sales as current levels — any significant increase could pressure margins. 3) The successful execution of the merger with Privi Fine Sciences and timely CAPEX deployment are critical to achieving long-term targets. 4) Regulatory and ESG compliance, while well-managed, may require ongoing investment amid tightening environmental norms.
📋 Recent Filings
-
Announcement 11 August 2026Privi Speciality Chemicals announced it will attend an investor conference on August 18, 2026, with MOSL Mumbai hosting a 1x1/group meeting starting a...
-
🟡 Board Meeting 10 August 2026The 41st Annual General Meeting of Privi Speciality Chemicals Limited was held on August 7, 2026, where shareholders approved all resolutions includin...
-
🟡 Board Meeting 30 July 2026The Board of Privi Speciality Chemicals Limited approved unaudited standalone and consolidated financial results for Q1 June 2026 at its July 30, 2026...
-
Announcement 30 July 2026Privi Speciality Chemicals reported Q1 FY27 revenue of Rs 681.42 Cr, up 20.01% YoY, with EBITDA at Rs 167.47 Cr (+18.73%) and PAT at Rs 84.21 Cr (+35....
-
Announcement 30 July 2026Privi Speciality Chemicals announced unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, approved by its Boar...
-
Announcement 23 July 2026Privi Speciality Chemicals announced its Q1 FY27 earnings conference call scheduled for July 31, 2026 at 3:30 p.m. IST to discuss operational and fina...
-
🔴 annual report 10 July 2026Privi Speciality Chemicals Limited released its Business Responsibility and Sustainability Report for FY 2025-26, highlighting its standalone disclosu...
-
share transfer 7 July 2026Privi Speciality Chemicals Limited received a SEBI-mandated share transfer agent certificate for Q1 FY2026 ending June 30, 2026, confirming dematerial...
-
🟡 concall transcript 30 June 2026Privi Speciality Chemicals reported 19.22% YoY revenue growth to Rs 666 crore in Q1 FY27, with 25% margins and EBITDA of Rs 167.47 crore (24.58% margi...
-
Financial Results 26 June 2026Privi Speciality Chemicals Limited announced that its trading window will close from July 1, 2026, until 48 hours after the un-audited Q1 results for ...
🧠 Analyst's Read
Privi Speciality Chemicals is executing a clear, capital-intensive growth strategy with improving operational efficiency and shareholder-friendly returns. The key watchpoints are the successful integration of the merger, execution of Phase-2 CAPEX, and sustainability of margins amid scaling. While financial metrics remain strong, long-term value hinges on delivery of strategic targets and managing external risks like export exposure and input costs.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when PRIVISCL files new disclosures
Track PRIVISCL filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track PRIVISCL — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd